Lymphedema Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.87 Billion |
| Market Size (2029) | USD 1.34 Billion |
| CAGR (2024 - 2029) | 9.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Lymphedema Treatment Market Analysis
The Lymphedema Treatment Market size is estimated at USD 0.87 billion in 2024, and is expected to reach USD 1.34 billion by 2029, growing at a CAGR of 9% during the forecast period (2024-2029).
The major factors driving the growth of the lymphedema treatment market include the rising number of lymphedema cases, technological advancements, and growing treatment awareness. For instance, according to the data released by the WHO in June 2023, globally, an estimated 25 million men are affected with lymphatic filariasis, and over 15 million people are currently suffering from lymphoedema. In addition, according to the data released by the Lymphatic Education & Research Network in May 2023, up to 250 million people worldwide have lymphedema.
Furthermore, the rising number of lymphedema hospitalization rates coupled with cancer across the world are set to drive the market growth during the forecast period. For instance, as per the data published by the Australian Institute of Health and Welfare (AIHW) in June 2023, the age-standardized rate of hospitalizations for lymphoedema in Australia was 30 per 100,000 population (9,400 hospitalizations) in 2022. As per the same source, some types of lymphoedema are related to cancer treatment, and based on projected new cancer cases for 2022, around 4,100 people with breast cancer and between 1,600 and 5,100 people with melanoma of the skin will go on to develop secondary lymphoedema. Thus, the country's high number of lymphoedema hospitalization rates are estimated to drive market growth during the forecast period.
Moreover, the active involvement of government organizations in fostering lymphatic treatment research worldwide is set to create lucrative market growth opportunities during the forecast period. For instance, in August 2022, the inclusion of Lymphatic Diseases and Lymphedema in the Senate FY 2023 Appropriations bill, specifically within the Peer-Reviewed Medical Research Program (PRMRP), is of enormous consequence for both researchers and the patient community. Aligning the lymphatic diseases and highlighting the potential benefits of lymphatic research opens up opportunities to understand and treat conditions that have systemic impacts on health. This development is expected to drive growth in the lymphatic treatment market by fostering innovative research, leading to new treatments and therapies for these conditions.
Therefore, factors such as the rising prevalence of lymphedema and the active involvement of government organizations in fostering lymphatic treatment research worldwide are set to drive the market growth during the forecast period. However, factors such as limited awareness, access to specialized care, and high treatment costs may restrain the market growth during the forecast period.
Lymphedema Treatment Market Trends
Compression Therapy Segment is Expected to Witness Significant Growth Over the Forecast Period
Compression therapy in lymphedema treatment involves applying pressure to the affected area using specialized garments, such as compression stockings or bandages. This pressure helps promote the movement of lymphatic fluid, reduce swelling, and support the tissues.
The growth of the compression therapy segment in the lymphedema treatment market can be attributed to various advantages offered by the use of compression therapy in the drainage of excess lymphatic fluid, advancements in compression garment technology, and a rising number of strategies performed by prominent players. For instance, according to the article published by the Wounds Australia Journal in February 2022, compression therapy is considered the gold standard treatment for lymphoedema as it significantly reduces limb volume in individuals with lymphoedema, with the effect commencing within hours of application of compression. As per the same source, compression therapy reduces pain and other symptoms, such as limb heaviness. Therefore, due to the various advantages offered by compression therapy and its acceptance as a gold standard for the treatment of lymphedema, it is set to drive the market growth during the forecast period.
Furthermore, the active participation of the prominent players in the launch of advanced compression therapy devices and a surging number of investments are projected further to enhance the segment growth during the study period. For instance, in February 2022, Koya Medical, a healthcare company, secured an investment of USD 26 million in series B funding to advance its portfolio of active compression therapies for lymphedema and venous disorders.
Therefore, factors such as various advantages offered by compression therapy and the active participation of prominent players in the launch of advanced compression therapy devices worldwide are set to drive the segment growth during the forecast period.
North America is Expected to Dominate the Lymphedema Treatment Market
The lymphedema treatment market in North America is expected to register significant growth during the forecast period owing to the rising cases of lymphedema across the United States, Canada, and Mexico and the increasing number of product launches.
The high prevalence of lymphedema in the United States and the high risk of the development of lymphedema among cancer survivors in the country are set to drive the market growth during the forecast period. For instance, according to the data published by the Lymphatic Education & Research Network in February 2022, an estimated 10 million people lived with lymphedema (LE) in the United States in 2022. As per the same source, approximately 30% of breast cancer survivors in the United States acquire debilitating LE. Similarly, as per the article published by the Canadian Medical Association (CMA) Journal in April 2022, breast cancer–related lymphedema (BCRL) is a lifelong condition affecting approximately 20% of Canadian women who undergo treatment for breast cancer.
Furthermore, the rising number of investments by government organizations in the region is also estimated to drive market growth during the forecast period. For instance, as per the article published by the National Institute of Health (NIH) in March 2023, the United States government invested around USD 12 million in lymphedema research in the country in 2023. Moreover, the rising number of product developments in the country is also projected to drive market growth during the forecast period. For instance, in October 2022, ImpediMed Limited announced the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare. The pilot program will consist of an initial rollout of five SOZO units to establish lymphedema screening services for breast cancer patients in centers across the United States. Upon completing the pilot program, GenesisCare will evaluate a staged expansion to additional sites in the United States.
Therefore, factors such as the high prevalence of lymphedema, the rising number of investments by government organizations, and the surging number of product launches are projected to accelerate market growth during the forecast period.
Lymphedema Treatment Industry Overview
The lymphedema treatment market is semi-consolidated due to the presence of several companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including PAUL HARTMANN AG, 3M, AIROS Medical Inc., Riancorp., and KOYA MEDICAL.
Lymphedema Treatment Market Leaders
-
PAUL HARTMANN AG
-
3M
-
AIROS Medical, Inc.
-
Riancorp
-
KOYA MEDICAL.
*Disclaimer: Major Players sorted in no particular order
Lymphedema Treatment Market News
• In June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema.
• In October 2022, ImpediMed announced the U.S. launch of a lymphedema prevention program with Genesis Care, a global organization dedicated to the care of cancer patients.
Lymphedema Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic and Infectious Disease Globally
4.2.2 Increasing Awareness Programs Regarding Lymphedema
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Treatment Type
5.1.1 Compression Therapy
5.1.2 Surgery
5.1.3 Laser Therapy
5.1.4 Other Treatment Types
5.2 By Type
5.2.1 Secondary Lymphedema
5.2.2 Primary Lymphedema
5.3 By Affected Area
5.3.1 Lower Extremity
5.3.2 Upper Extremity
5.3.3 Genitalia
5.4 By End User
5.4.1 Hospitals
5.4.2 Specialty Clinics
5.4.3 Ambulatory Surgical Centers
5.4.4 Other End Users
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 medi
6.1.2 PAUL HARTMANN AG
6.1.3 3M
6.1.4 AIROS Medical, Inc.
6.1.5 Riancorp.
6.1.6 KOYA MEDICAL
6.1.7 Huntleigh Healthcare Limited.
6.1.8 Tactile Medical.
6.1.9 Mego Afek ltd.
6.1.10 SIGVARIS GROUP.
6.1.11 ThermoTek
6.1.12 L&R Group
6.1.13 HERANTIS PHARMA Plc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Lymphedema Treatment Industry Segmentation
Lymphedema is a chronic medical condition characterized by the abnormal accumulation of lymphatic fluid, typically in the arms or legs, causing swelling and discomfort. Management typically involves comprehensive care to reduce swelling, which includes compression therapy, manual lymphatic drainage, and other treatments. The lymphedema treatment market is segmented by treatment type, type, affected area, end-user, and geography. By treatment type, the market is segmented into compression therapy, surgery, laser therapy, and other treatment types. Other treatment types include drugs, exercise, and manual lymph. By type, the market is segmented into secondary lymphedema and primary lymphedema. By affected area, the market is segmented into lower extremity, upper extremity, and genitalia. By end user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and other end users. Other end-users include homecare settings and rehabilitation centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across regions. For each segment, the market sizing and forecasts were made on the basis of revenue (USD).
| By Treatment Type | |
| Compression Therapy | |
| Surgery | |
| Laser Therapy | |
| Other Treatment Types |
| By Type | |
| Secondary Lymphedema | |
| Primary Lymphedema |
| By Affected Area | |
| Lower Extremity | |
| Upper Extremity | |
| Genitalia |
| By End User | |
| Hospitals | |
| Specialty Clinics | |
| Ambulatory Surgical Centers | |
| Other End Users |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Lymphedema Treatment Market Research FAQs
How big is the Lymphedema Treatment Market?
The Lymphedema Treatment Market size is expected to reach USD 0.87 billion in 2024 and grow at a CAGR of 9% to reach USD 1.34 billion by 2029.
What is the current Lymphedema Treatment Market size?
In 2024, the Lymphedema Treatment Market size is expected to reach USD 0.87 billion.
Who are the key players in Lymphedema Treatment Market?
PAUL HARTMANN AG, 3M, AIROS Medical, Inc., Riancorp and KOYA MEDICAL. are the major companies operating in the Lymphedema Treatment Market.
Which is the fastest growing region in Lymphedema Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Lymphedema Treatment Market?
In 2024, the North America accounts for the largest market share in Lymphedema Treatment Market.
What years does this Lymphedema Treatment Market cover, and what was the market size in 2023?
In 2023, the Lymphedema Treatment Market size was estimated at USD 0.79 billion. The report covers the Lymphedema Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Lymphedema Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Lymphedema Treatment Industry Report
Statistics for the 2024 Lymphedema Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Lymphedema Treatment analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
